Search results
Results from the WOW.Com Content Network
The aims of EULAR are to reduce the burden of rheumatic diseases on the individual and society and to improve the treatment, prevention and rehabilitation of musculoskeletal diseases. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with musculoskeletal diseases by the ...
Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. [1] It targets interferon a. [2] Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials. [3] [4] [5]
Lupus nephritis is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE) and childhood-onset systemic lupus erythematosus which is a more severe form of SLE that develops in children up to 18 years old; both are autoimmune diseases. [3] [4] It is a type of glomerulonephritis in which the glomeruli become inflamed.
Children up to 18 years old develop a more severe form of SLE termed childhood-onset systemic lupus erythematosus. [4] The cause of SLE is not clear. [1] It is thought to involve a combination of genetics and environmental factors. [5] Among identical twins, if one is affected there is a 24% chance the other one will also develop the disease. [1]
Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells.. Elevated CD22 and other B-cell receptor (BCR) proteins are associated with SLE. "Epratuzumab's mechanism of action transfers these BCR proteins to helper cells called effector cells which reduces B-cell destruction and epratuzumab's impact on the body's immune system" [6] via a process called trogocytosis. [3]
Immunofluorescence pattern of SS-A and SS-B antibodies. Produced using serum from a patient on HEp-20-10 cells with a FITC conjugate. Anti-SSA autoantibodies (anti–Sjögren's-syndrome-related antigen A autoantibodies, also called anti-Ro, or similar names including anti-SSA/Ro, anti-Ro/SSA, anti–SS-A/Ro, and anti-Ro/SS-A) are a type of anti-nuclear autoantibodies that are associated with ...
The PRISMA flow diagram, depicting the flow of information through the different phases of a systematic review. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) is an evidence-based minimum set of items aimed at helping scientific authors to report a wide array of systematic reviews and meta-analyses, primarily used to assess the benefits and harms of a health care ...
The cause of diffuse proliferative glomerulonephritis (DPGN) depends on the severity of the disease. DPGN is a secondary disease, in that a disease that a patient already has causes DPGN to occur. The most common associated disease of DPGN is severe systemic lupus erythematosus(SLE). [4] Specifically, Lupus nephritis class IV. [5]